6.15 (0.83%)
  • Advice
  • Hold
As on 06 February, 2023 | 15:06 BSE: 500257 NSE: LUPIN

Lupin Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in Lupin

Start SIP

Lupin Share Price

  • Over 1 Month 1.1%
  • Over 3 Month 4.76%
  • Over 6 Month 18.87%
  • Over 1 Year -17.11%

Lupin Key Statistics

P/E Ratio 497.1
PEG Ratio 4.5
Market Cap Cr 33,913
Price to Book Ratio 2.8
EPS -4.9
Dividend 0.5
Relative Strength Index 45.62
Money Flow Index 43.05
MACD Signal 0.65
Average True Range 15.81

Lupin Investment Rating

  • Master Rating:
  • Lupin (Nse) has an operating revenue of Rs. 15,933.32 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of -8% needs improvement, ROE of -12% is poor and needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 7% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 6% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 35 which is a POOR score indicating inconsistency in earnings, a RS Rating of 54 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 95 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Lupin Financials
IndicatorSep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 2,8292,6842,504
Operating Expenses Qtr Cr 2,5152,4442,354
Operating Profit Qtr Cr 314289501
Depreciation Qtr Cr 138130131
Interest Qtr Cr 182025
Tax Qtr Cr 2428397
Net Profit Qtr Cr 149117-36

Lupin Technicals


Current Price
6.65 (0.9%)
  • Bullish Moving Average
  • ___
  • 12
  • Bearish Moving Average
  • ___
  • 4
  • 20 Day
  • 746.03
  • 50 Day
  • 741.32
  • 100 Day
  • 727.96
  • 200 Day
  • 734
  • 20 Day
  • 750.03
  • 50 Day
  • 748.61
  • 100 Day
  • 722.15
  • 200 Day
  • 689.71

Lupin Resistance and Support

First Resistance 746.79
Second Resistance 754.17
Third Resistance 761.04
RSI 45.62
MFI 43.05
MACD Single Line 0.65
MACD -1.59
First Resistance 732.54
Second Resistance 725.67
Third Resistance 718.29

Lupin Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 394,150 14,926,461 37.87
Week 629,124 32,104,218 51.03
1 Month 658,931 28,577,831 43.37
6 Month 1,351,300 40,511,964 29.98

Lupin Result Highlights

Lupin Synopsis

NSE-Medical-Generic Drugs

Lupin Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11771.67 Cr. and Equity Capital is Rs. 90.90 Cr. for the Year ended 31/03/2022. Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442.
Market Cap 33,893
Sales 11,149
Shares in Float 24.11
No of funds 548
Yield 0.54
Book Value 1.85
U/D Vol ratio 1.3
LTDebt / Equity
Alpha -0.03
Beta 0.87


Owner NameDec-22Sep-22Jun-22Mar-22
Promoters 47.1%47.11%47.1%
Mutual Funds 16.47%16.44%15.86%
Insurance Companies 11.39%10.96%10.82%
Foreign Portfolio Investors 13.98%13.81%14.27%
Financial Institutions/ Banks 0.14%0.14%0.14%
Individual Investors 8.06%8.41%8.59%
Others 2.86%3.13%3.22%

Lupin Management

Name Designation
Mrs. Manju D Gupta Chairman
Dr. Kamal K Sharma Vice Chairman
Mr. Nilesh D Gupta Managing Director
Ms. Vinita Gupta Executive Director & CEO
Mr. Ramesh Swaminathan Executive Director & Global CFO
Mr. Jean-Luc Belingard Independent Director
Ms. Christine Mundkur Independent Director
Mr. K B S Anand Independent Director
Dr. Punita Kumar-Sinha Independent Director
Mr. Mark D McDade Independent Director

Lupin Forecast

Price Estimates


Other Analyst Rating

Lupin Corporate Action

Date Purpose Remarks
2023-02-09 Quarterly Results
2022-11-09 Quarterly Results
2022-08-03 Quarterly Results
2022-05-18 Audited Results & Final Dividend
2022-02-03 Quarterly Results
Date Purpose Remarks
2022-07-15 FINAL Rs.4.00 per share(200%)Final Dividend
2021-07-28 FINAL Rs.6.50 per share(325%)Final Dividend

Lupin MF Shareholding

Name Amount(cr)
HDFC Balanced Advantage Fund Growth 51027
ICICI Prudential Balanced Advantage Fund Growth 44634
Kotak Flexicap Fund Growth 37418
ICICI Prudential Bluechip Fund Growth 35049
HDFC Flexi Cap Fund Growth 32155

About Company

Dr Desh Bandhu Gupta founded in 1968 in Mumbai, Lupin is one of the top pharmaceutical manufacturers. It has 15 manufacturing facilities, 6 API facilities, 7 research facilities and more than 23 global offices. 

Lupin ranks 6th by sales in India. It ranks #2 in respiratory and #3 in cardiac and anti-diabetes segments. While the market growth in the chronic disease portfolio has been 11% in the last five years, Lupin has been growing at 14% YoY.
Over the last 4 years, it has invested over $1bn in R&D in areas of biosimilars, complex generics, long-acting complex injectables, inhalation and speciality portfolio. 

Business Verticals

1. Global Formulations
2. Active Pharmaceuticals Ingredients (API)
3. Biotech
4. Specialty Business
5. Over The Counter (OTC)
6. Biosimilars
7. Generic drugs

Company History

Lupin commenced operations in 1968 on Gudi Padwa as a vitamins manufacturer. It is named after the Lupin flower, which can tolerate infertile soils and poor climatic conditions. Its first major order was iron and folic acid tablets for mother and child healthcare programmes backed by the Government of India.

Today, it develops branded and generic formulations, APIs, and biotechnology products and sells across 100 markets, including the US, Japan, and Mexico. Lupin is one of the world's largest manufacturers of TB drugs. The company has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System, Gastro-Intestinal, Anti-Infective, and Non-Steroidal Anti-Inflammatory Drugs. 


1968 - Dr Desh Bandhu Gupta started Lupin.

1972 - Lupin Laboratories Pvt. Ltd. was incorporated.

1979 - They commissioned the first formulation plant and R&D Centre at Aurangabad.

1981 - They started the production of Ethambutol.

1987 - Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar went on stream.

1988 - Commenced Lupin Human Welfare and Research Foundation (LHWRF).

1989 - Started Lupin Chemicals (Thailand) Ltd. Received U.S. FDA approvals for the Ankleshwar and Mandideep plants.

1991 - Initiated the production of injectable Cephalosporin at Mandideep.

1992 - Commenced a sterile fermentation plant for injectable Cephalosporins at Mandideep.

1993 - Lupin Laboratories Ltd. and Lupin Chemicals Ltd. floated their IPOs.

1997 - Three facilities received U.S. FDA approvals.

2000 - Another plant received US FDA approval.

2001 - Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd. to form Lupin Ltd. and established the Lupin Research Park in Pune. Lupin became the only Asian pharmaceutical company to receive U.S. FDA approvals for its sterile Cephalosporin facility.

2002 - ORG-Marg rated Rablet as the 2nd best launch of 2002-03; patent filings exceed 100.

2003 - Received WHO approval for the formulation plant at Aurangabad. Lupin Pharmaceuticals Inc. USA is formed.

2004 - Started U.S. brands’ business with the launch of Suprax.

2005 - Commenced its generics business in the U.S. Implemented ESOP.

2006 - Announced the issue of FCCBs, with a listing on the Singapore Stock Exchange.

2007 - Acquired Kyowa Pharmaceuticals of Japan; and Rubamin Laboratories of India.

2008 - Acquired Hormosan Pharma GmbH, Germany. Also acquired stakes in Generic. Health Pty Ltd., Australia and Pharma Dynamics, South Africa.

2009 - Acquired majority stake in Multi-Care Pharmaceuticals Inc., Philippines.

2010 - Lupin ranked the 5th largest generic player in the U.S.

2011 - Began commercial production at the new oral solid dosage facility at Pithampur; acquired I’rom Pharmaceuticals, Japan and of worldwide rights for the Goanna Brand.

2012 - Lupin enters Nifty 50.

2014 - Acquired Nanomi BV of the Netherlands and Laboratorios Grin S.A. De C.V., Mexico.

2015 - Acquired Pharma Dynamics, South Africa, Medquimica Industria, Brazil; Specialty product portfolio of Temmler Pharma GMBH & Co., Germany.

2016 - Acquired Gavis Pharma, U.S; launched a new plant at Tottori, Japan.

2017 - Launched Softovac in the OTC segment; acquired Symbiomix Therapeutics, U.S.

2019 - Divestment of Kyowa Pharmaceutical Industry Co. Ltd., in Osaka.

2020 - Launched Etanercept Biosimilar in EU and gProAir, a key inhalation product.

Lupin FAQs

What is Share Price of Lupin ?

Lupin share price is ₹745 As on 06 February, 2023 | 14:52

What is the Market Cap of Lupin ?

The Market Cap of Lupin is ₹33913.2 Cr As on 06 February, 2023 | 14:52

What is the P/E ratio of Lupin ?

The P/E ratio of Lupin is 497.1 As on 06 February, 2023 | 14:52

What is the PB ratio of Lupin ?

The PB ratio of Lupin is 2.8 As on 06 February, 2023 | 14:52

What were the company's reported sales and net income in 2022?

For the year ending March 2022, Lupin reported a consolidated sales figure of INR 16,405 crores and a net loss of INR 1,528 crores. Its standalone sales and net loss for the same period stood at INR 11,772 crores and 189 crores respectively.

What is the future of Lupin Limited's shares?

Lupin’s future looks slightly bleak. The company has shown a negative net profit growth rate of 2.18% and revenue growth of 3.10% for the past 3 years. However, the company is virtually debt-free.

How to buy Lupin’s shares?

You can easily buy and sell the company's shares by creating a Demat account with 5Paisa.